CY1124528T1 - Ν-υποκατεστημενα παραγωγα ινδολης - Google Patents
Ν-υποκατεστημενα παραγωγα ινδοληςInfo
- Publication number
- CY1124528T1 CY1124528T1 CY20211100841T CY211100841T CY1124528T1 CY 1124528 T1 CY1124528 T1 CY 1124528T1 CY 20211100841 T CY20211100841 T CY 20211100841T CY 211100841 T CY211100841 T CY 211100841T CY 1124528 T1 CY1124528 T1 CY 1124528T1
- Authority
- CY
- Cyprus
- Prior art keywords
- indole derivatives
- substituted indole
- formula
- derivatives
- prostaglandin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Η παρούσα εφεύρεση σχετίζεται με παράγωγα του τύπου (Ι), Τύπος (Ι), όπου το R1 και R2 είναι όπως περιγράφονται στην περιγραφή, με την παρασκευή τους, με τα φαρμακευτικώς αποδεκτά άλατα τους, και τη χρήση τους ως φαρμακευτικά, με τις φαρμακευτικές συνθέσεις που περιέχουν μία ή περισσότερες ενώσεις του τύπου (Ι) και ειδικά για τη χρήση τους ως ρυθμιστές του υποδοχέα ΕΡ2 προσταγλανδίνης 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2017062008 | 2017-05-18 | ||
PCT/EP2018/062865 WO2018210995A1 (en) | 2017-05-18 | 2018-05-17 | N-substituted indole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124528T1 true CY1124528T1 (el) | 2022-07-22 |
Family
ID=62186481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100841T CY1124528T1 (el) | 2017-05-18 | 2021-09-27 | Ν-υποκατεστημενα παραγωγα ινδολης |
Country Status (32)
Country | Link |
---|---|
US (2) | US20200069686A1 (el) |
EP (1) | EP3625224B1 (el) |
JP (1) | JP7065117B2 (el) |
KR (1) | KR102650756B1 (el) |
CN (1) | CN110621666A (el) |
AR (1) | AR111806A1 (el) |
AU (1) | AU2018269667B2 (el) |
BR (1) | BR112019024114A2 (el) |
CA (1) | CA3063637A1 (el) |
CL (1) | CL2019003257A1 (el) |
CO (1) | CO2019010804A2 (el) |
CR (1) | CR20190567A (el) |
CY (1) | CY1124528T1 (el) |
DK (1) | DK3625224T3 (el) |
EA (1) | EA039630B1 (el) |
ES (1) | ES2894124T3 (el) |
HR (1) | HRP20211532T1 (el) |
HU (1) | HUE056406T2 (el) |
IL (1) | IL270616B (el) |
LT (1) | LT3625224T (el) |
MA (1) | MA49127B1 (el) |
MX (1) | MX2019013639A (el) |
PE (1) | PE20191787A1 (el) |
PH (1) | PH12019502562A1 (el) |
PL (1) | PL3625224T3 (el) |
PT (1) | PT3625224T (el) |
RS (1) | RS62441B1 (el) |
SG (1) | SG11201908660RA (el) |
SI (1) | SI3625224T1 (el) |
TW (1) | TWI768043B (el) |
UA (1) | UA124748C2 (el) |
WO (1) | WO2018210995A1 (el) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
ES2929309T3 (es) | 2017-05-18 | 2022-11-28 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor PGE2 |
HRP20211533T1 (hr) | 2017-05-18 | 2022-01-07 | Idorsia Pharmaceuticals Ltd | Derivati fenila kao modulatori receptora pge2 |
EP3625228B1 (en) | 2017-05-18 | 2021-07-07 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
WO2021060281A1 (ja) * | 2019-09-24 | 2021-04-01 | Agc株式会社 | プロスタグランジンe2レセプターep2/ep4デュアルアンタゴニスト |
CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
JPWO2022102731A1 (el) | 2020-11-13 | 2022-05-19 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2000234451B2 (en) | 2000-03-24 | 2005-09-29 | Asterand Uk Acquisition Limited | Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
JP2005532291A (ja) | 2002-04-12 | 2005-10-27 | ファイザー株式会社 | 抗炎症薬および鎮痛薬としてのピラゾール化合物 |
BR0309305A (pt) | 2002-04-12 | 2005-02-15 | Pfizer | Compostos de imidazol como agentes antiinflamatórios e analgésicos |
JP2006506327A (ja) | 2002-05-23 | 2006-02-23 | セラテクノロジーズ インコーポレイティド | プロスタグランジンe2の受容体サブタイプep4のアンタゴニスト・ポリペプチド |
AU2004207675B2 (en) | 2003-01-29 | 2010-05-20 | Asterand Uk Acquisition Limited | EP4 receptor antagonists |
PE20050347A1 (es) * | 2003-08-26 | 2005-05-04 | Teijin Pharma Ltd | Derivados de pirrolopirimidina |
EP1663979B1 (en) | 2003-09-03 | 2013-10-09 | RaQualia Pharma Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
BRPI0510598A (pt) | 2004-05-04 | 2007-11-20 | Pfizer | compostos de amida de aril ou heteroaril substituìdos |
JP4054368B2 (ja) | 2004-05-04 | 2008-02-27 | ファイザー株式会社 | 置換メチルアリール又はヘテロアリールアミド化合物 |
HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
EP1885722B1 (en) | 2005-05-19 | 2011-11-16 | Merck Canada Inc. | Quinoline derivatives as ep4 antagonists |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
ES2392192T3 (es) | 2006-04-24 | 2012-12-05 | Merck Canada Inc. | Derivados de indol amida como antagonistas del receptor EP4 |
JP5183628B2 (ja) | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ep4受容体リガンドとしてのインドリンアミド誘導体 |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
JP4960450B2 (ja) | 2006-07-14 | 2012-06-27 | ノバルティス アーゲー | Alk−5阻害剤としてのピリミジン誘導体 |
US8969394B2 (en) | 2006-08-11 | 2015-03-03 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
AU2008221194B2 (en) | 2007-02-26 | 2013-06-27 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists |
JPWO2008123207A1 (ja) | 2007-03-26 | 2010-07-15 | アステラス製薬株式会社 | オルニチン誘導体 |
US8003661B2 (en) | 2007-03-26 | 2011-08-23 | Merck Canada Inc. | Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists |
EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
JP5408434B2 (ja) | 2007-07-03 | 2014-02-05 | アステラス製薬株式会社 | アミド化合物 |
EP2565191B1 (en) | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
EP2320906B1 (en) | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
WO2010032123A1 (en) | 2008-09-19 | 2010-03-25 | Biotechnology Research Corporation Limited | Triterpenoid compounds and methods of use thereof |
JP2012503605A (ja) | 2008-09-25 | 2012-02-09 | メルク カナダ インコーポレイテッド | Ep4受容体アンタゴニストとしてのベータ−カルボリンスルホニルウレア誘導体 |
AU2011254550B2 (en) | 2010-05-21 | 2013-11-07 | Noviga Research Ab | Novel pyrimidine derivatives |
ES2610185T3 (es) | 2010-09-21 | 2017-04-26 | Eisai R&D Management Co., Ltd. | Composición farmacéutica |
NZ609887A (en) | 2010-09-29 | 2015-01-30 | Nb Health Lab Co Ltd | Antibody against human prostaglandin e2 receptor ep4 |
US8828987B2 (en) | 2010-12-10 | 2014-09-09 | Rottapharm Biotech S.R.L. | Pyridine amide derivatives as EP4 receptor antagonists |
WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
CA2830129C (en) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Novel pyrimidine derivatives |
US9181279B2 (en) | 2011-07-04 | 2015-11-10 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor antagonists |
EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
SG10201704095UA (en) | 2012-04-24 | 2017-06-29 | Vertex Pharma | Dna-pk inhibitors |
JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫-1h-異喹啉化合物 |
PL3009426T3 (pl) | 2013-06-12 | 2018-09-28 | Kaken Pharmaceutical Co., Ltd. | Pochodna 4-alkinyloimidazolu i lek zawierający tę pochodną jako składnik aktywny |
MX2016002544A (es) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
PL3041827T3 (pl) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Limited | Pochodne 1,2,4-oksadiazolu jako immunomodulatory |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
PT3057959T (pt) | 2013-10-17 | 2018-06-04 | Vertex Pharma | Inibidores de adn-pk |
CN105793236B (zh) | 2013-12-17 | 2017-10-10 | 伊莱利利公司 | 二甲基苯甲酸化合物 |
RS56615B1 (sr) | 2013-12-17 | 2018-02-28 | Lilly Co Eli | Derivati fenoksietil cikličnih amina i njihova aktivnost kao modulatora ep4 receptora |
TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ep4配體之新穎苯并咪唑衍生物 |
TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
CN106572993B (zh) | 2014-05-23 | 2019-07-16 | 卫材R&D管理有限公司 | Ep4拮抗剂在制备治疗癌症的药物中的应用 |
WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
WO2016054807A1 (en) * | 2014-10-10 | 2016-04-14 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
NZ733575A (en) | 2015-01-09 | 2022-10-28 | Ono Pharmaceutical Co | Tricyclic spiro compound |
CN108368127B (zh) | 2015-07-23 | 2020-12-11 | 武田药品工业株式会社 | 化合物及其作为ep4受体拮抗剂的用途 |
WO2017066633A1 (en) | 2015-10-16 | 2017-04-20 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
-
2018
- 2018-05-17 HU HUE18725223A patent/HUE056406T2/hu unknown
- 2018-05-17 WO PCT/EP2018/062865 patent/WO2018210995A1/en unknown
- 2018-05-17 EP EP18725223.4A patent/EP3625224B1/en active Active
- 2018-05-17 LT LTEPPCT/EP2018/062865T patent/LT3625224T/lt unknown
- 2018-05-17 HR HRP20211532TT patent/HRP20211532T1/hr unknown
- 2018-05-17 SG SG11201908660R patent/SG11201908660RA/en unknown
- 2018-05-17 CA CA3063637A patent/CA3063637A1/en active Pending
- 2018-05-17 PT PT18725223T patent/PT3625224T/pt unknown
- 2018-05-17 TW TW107116708A patent/TWI768043B/zh active
- 2018-05-17 KR KR1020197037058A patent/KR102650756B1/ko active IP Right Grant
- 2018-05-17 BR BR112019024114-0A patent/BR112019024114A2/pt unknown
- 2018-05-17 CR CR20190567A patent/CR20190567A/es unknown
- 2018-05-17 US US16/614,268 patent/US20200069686A1/en not_active Abandoned
- 2018-05-17 AU AU2018269667A patent/AU2018269667B2/en active Active
- 2018-05-17 JP JP2019563494A patent/JP7065117B2/ja active Active
- 2018-05-17 UA UAA201911973A patent/UA124748C2/uk unknown
- 2018-05-17 PL PL18725223T patent/PL3625224T3/pl unknown
- 2018-05-17 SI SI201830413T patent/SI3625224T1/sl unknown
- 2018-05-17 CN CN201880031869.9A patent/CN110621666A/zh active Pending
- 2018-05-17 EA EA201992679A patent/EA039630B1/ru unknown
- 2018-05-17 MX MX2019013639A patent/MX2019013639A/es unknown
- 2018-05-17 RS RS20211259A patent/RS62441B1/sr unknown
- 2018-05-17 ES ES18725223T patent/ES2894124T3/es active Active
- 2018-05-17 DK DK18725223.4T patent/DK3625224T3/da active
- 2018-05-17 MA MA49127A patent/MA49127B1/fr unknown
- 2018-05-17 PE PE2019002413A patent/PE20191787A1/es unknown
- 2018-05-17 AR ARP180101311A patent/AR111806A1/es unknown
-
2019
- 2019-09-30 CO CONC2019/0010804A patent/CO2019010804A2/es unknown
- 2019-11-13 IL IL270616A patent/IL270616B/en unknown
- 2019-11-14 CL CL2019003257A patent/CL2019003257A1/es unknown
- 2019-11-15 PH PH12019502562A patent/PH12019502562A1/en unknown
-
2021
- 2021-09-27 CY CY20211100841T patent/CY1124528T1/el unknown
-
2022
- 2022-11-27 US US18/058,873 patent/US20230165859A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124528T1 (el) | Ν-υποκατεστημενα παραγωγα ινδολης | |
CY1124913T1 (el) | Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2 | |
CY1123645T1 (el) | Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
CY1122870T1 (el) | Νεα πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που τα περιεχουν | |
CY1123069T1 (el) | Νεα (ετερο)αρυλ-υποκατεστημενα-πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
CY1122560T1 (el) | Νεα παραγωγα αμμωνιου, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουναυτα | |
CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1116150T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
CY1120378T1 (el) | Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης) | |
PH12019500188A1 (en) | Piperidine cxcr7 receptor modulators | |
CY1124608T1 (el) | Παραγωγα φαινυλιου ως ρυθμιστες υποδοχεα pge2 | |
CY1124245T1 (el) | Τρικυκλικα συγχωνευμενα παραγωγα πυριδινης-2-ενα και η χρηση τους ως αναστολεις brd4 | |
CY1124799T1 (el) | Παραγωγα πυριμιδινης ως ρυθμιστες υποδοχεα pge2 | |
CY1121596T1 (el) | Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα | |
EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
CY1122731T1 (el) | Διαμορφωτες υποδοχεα οιστρογονων | |
EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
TR201900680T4 (tr) | CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri. | |
CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
TR201901977T4 (tr) | Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri. | |
TR201904639T4 (tr) | Muskarinik M1 reseptörü pozitif allosterik modülatörler. |